Home Other Sections Medical News Soy Lecithin-NSAID Combo Drug Protects Against Cancer with Few Side Effects

Soy Lecithin-NSAID Combo Drug Protects Against Cancer with Few Side Effects

Affiliate Disclosure

In compliance with the FTC guidelines, please assume the following about all links, posts, photos and other material on this website: (...)


Soy Lecithin-NSAID Combo Drug Protects Against Cancer with Few Side EffectsAt the point when researchers at the University of Texas Health Science Center at Houston (UTHealth) utilized a substance found in soybeans with a non-steroidal anti-inflammatory drug (NSAID), they broadened its anticancer properties and decreased its side effects.

Results of the preclinical investigation of phosphatidylcholine, regularly known as lecithin, has been published inside the journal Oncology Letters.

The outcomes promote the use of NSAIDs with phosphatidylcholine to prevent and treat colorectal cancer.

The NSAID indomethacin identified with phosphatidylcholine was once considered in a careful assessment with three different NSAIDs (one is aspirin).

Soy Lecithin-NSAID Combination


According to the results, the combination offered advanced colorectal cancer treatment with less gastrointestinal bleeding.

The examination was done in a mouse model and in research facility tests.

Colorectal cancer is the third fundamental driver of cancer deaths in the United States and is said to claim 50,630 lives this year.

NSAIDs and Colorectal Cancer

NSAIDs work by diminishing the elements that lead to inflammation, pain and fever. They are utilized to avert heart disease and reduce joint pain.

NSAIDs, mainly aspirin, also works against colorectal cancer.

The scientists asserted that numerous cancers are based on inflammation

The anti-inflammatory medicines even have the potential for cancer treatment.

However, when taken daily for months to years, NSAIDs can bring about issues. The gastrointestinal harm is worse for non-aspirin NSAIDs like indomethacin.

The specialists remarked that this is a front line preclinical investigation on the utilization of phosphatidylcholine to alleviate the reactions of NSAIDs and protect against various cancers.